# Long-Term Assessment of Remyelinating Therapy

> **NCT02657915** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 52 (actual)

## Conditions studied

- Acute Optic Neuritis

## Interventions

- **DRUG:** Placebo
- **DRUG:** BIIB033 100mg/Kg

## Key facts

- **NCT ID:** NCT02657915
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-10
- **Primary completion:** 2017-01-23
- **Final completion:** 2017-01-23
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2019-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02657915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02657915, "Long-Term Assessment of Remyelinating Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02657915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*